Clearmind Reports Intranasal MEAI Formulation Feasibility with Stable Solubility
CMND•Clearmind Medicine’s formulation feasibility study demonstrated intranasal MEAI can be incorporated into a stable, fully soluble solution under initial testing conditions. This additional delivery route for the proprietary 5-Methoxy-2-aminoindane candidate aims to enhance treatment options for alcohol use disorder with improved patient experience and therapeutic performance.
1. Study Demonstrates Intranasal Feasibility
Clearmind initiated formulation-feasibility studies on intranasal delivery of its MEAI (5-Methoxy-2-aminoindane) candidate, focusing on compatibility with nasal formulation systems. Initial results showed MEAI could be formulated into a stable, fully soluble intranasal solution, providing a strong basis for further optimization and development.
2. Program Objectives and Development Path
The intranasal program targets alcohol use disorder by combining MEAI’s novel mechanism with an advanced drug delivery platform to improve patient convenience and therapeutic performance. With stability confirmed, Clearmind plans subsequent formulation optimization and preclinical assessments to advance toward clinical evaluation.
